Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1990 Aug;58(8):2459–2463. doi: 10.1128/iai.58.8.2459-2463.1990

Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells.

M Drancourt 1, M C Alessi 1, P Y Levy 1, I Juhan-Vague 1, D Raoult 1
PMCID: PMC258841  PMID: 2115024

Abstract

Hemostasis abnormalities have been described in patients with Mediterranean spotted fever and Rocky Mountain spotted fever. Evidence of the activation of the fibrinolytic system has been obtained in both diseases. After experimental Rocky Mountain spotted fever, an elevated level of fibrinogen was found in parallel with the activation of the fibrinolytic system and transient elevation of the tissue-type plasminogen activator. Later protein is mainly synthesized by endothelial cells. The ability to culture human endothelial cells in vitro provides a unique system to study the secretion of tissue-type plasminogen activator and of plasminogen activator inhibitor after rickettsial infection. Human vascular endothelial cells derived from the umbilical vein, when infected with Rickettsia conorii or Rickettsia rickettsii, secreted as much tissue-type plasminogen activator as control cells. The activity of plasminogen activator inhibitor however, was higher in the supernatants of infected cells than in those of control cells. This rickettsia-induced imbalance of the tissue-type plasminogen activator-inhibitor pair was a very early event after in vitro infection. The involvement of this system during Mediterranean spotted fever and Rocky Mountain spotted fever remains to be demonstrated.

Full text

PDF
2459

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Colucci M., Paramo J. A., Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest. 1985 Mar;75(3):818–824. doi: 10.1172/JCI111777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. GIMENEZ D. F. STAINING RICKETTSIAE IN YOLK-SAC CULTURES. Stain Technol. 1964 May;39:135–140. doi: 10.3109/10520296409061219. [DOI] [PubMed] [Google Scholar]
  3. Hanss M., Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med. 1987 Jan;109(1):97–104. [PubMed] [Google Scholar]
  4. Helmick C. G., Bernard K. W., D'Angelo L. J. Rocky Mountain spotted fever: clinical, laboratory, and epidemiological features of 262 cases. J Infect Dis. 1984 Oct;150(4):480–488. doi: 10.1093/infdis/150.4.480. [DOI] [PubMed] [Google Scholar]
  5. Jaffe E. A., Nachman R. L., Becker C. G., Minick C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973 Nov;52(11):2745–2756. doi: 10.1172/JCI107470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Juhan-Vague I., Valadier J., Alessi M. C., Aillaud M. F., Ansaldi J., Philip-Joet C., Holvoet P., Serradimigni A., Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost. 1987 Feb 3;57(1):67–72. [PubMed] [Google Scholar]
  7. Levin E. G. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci U S A. 1983 Nov;80(22):6804–6808. doi: 10.1073/pnas.80.22.6804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Loscalzo J., Braunwald E. Tissue plasminogen activator. N Engl J Med. 1988 Oct 6;319(14):925–931. doi: 10.1056/NEJM198810063191407. [DOI] [PubMed] [Google Scholar]
  9. Rao A. K., Schapira M., Clements M. L., Niewiarowski S., Budzynski A. Z., Schmaier A. H., Harpel P. C., Blackwelder W. C., Scherrer J. R., Sobel E. A prospective study of platelets and plasma proteolytic systems during the early stages of Rocky Mountain spotted fever. N Engl J Med. 1988 Apr 21;318(16):1021–1028. doi: 10.1056/NEJM198804213181603. [DOI] [PubMed] [Google Scholar]
  10. Raoult D., Drancourt A. M., Ardissone J. P. Enzyme secretion by human endothelial cells infected with Rickettsia conorii. Acta Virol. 1987 Aug;31(4):352–356. [PubMed] [Google Scholar]
  11. Raoult D., Weiller P. J., Chagnon A., Chaudet H., Gallais H., Casanova P. Mediterranean spotted fever: clinical, laboratory and epidemiological features of 199 cases. Am J Trop Med Hyg. 1986 Jul;35(4):845–850. doi: 10.4269/ajtmh.1986.35.845. [DOI] [PubMed] [Google Scholar]
  12. Raoult D., Zuchelli P., Weiller P. J., Charrel C., San Marco J. L., Gallais H., Casanova P. Incidence, clinical observations and risk factors in the severe form of Mediterranean spotted fever among patients admitted to hospital in Marseilles 1983-1984. J Infect. 1986 Mar;12(2):111–116. doi: 10.1016/s0163-4453(86)93508-5. [DOI] [PubMed] [Google Scholar]
  13. Silverman D. J. Adherence of platelets to human endothelial cells infected by Rickettsia rickettsii. J Infect Dis. 1986 Apr;153(4):694–700. doi: 10.1093/infdis/153.4.694. [DOI] [PubMed] [Google Scholar]
  14. Silverman D. J. Rickettsia rickettsii-induced cellular injury of human vascular endothelium in vitro. Infect Immun. 1984 Jun;44(3):545–553. doi: 10.1128/iai.44.3.545-553.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sprengers E. D., Kluft C. Plasminogen activator inhibitors. Blood. 1987 Feb;69(2):381–387. [PubMed] [Google Scholar]
  16. Verheijen J. H., Chang G. T., Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost. 1984 Jul 29;51(3):392–395. [PubMed] [Google Scholar]
  17. Vicente V., Alberca I., Ruiz R., Herrero I., Gonzalez R., Portugal J. Coagulation abnormalities in patients with Mediterranean spotted fever. J Infect Dis. 1986 Jan;153(1):128–131. doi: 10.1093/infdis/153.1.128. [DOI] [PubMed] [Google Scholar]
  18. Vicente V., Alegre A., Ruiz R., Herrero J. I., Portugal J., Alberca I. Kinin-prekallikrein system in Mediterranean spotted fever. J Infect Dis. 1986 Sep;154(3):541–541. doi: 10.1093/infdis/154.3.541. [DOI] [PubMed] [Google Scholar]
  19. Walker D. H., Firth W. T., Edgell C. J. Human endothelial cell culture plaques induced by Rickettsia rickettsii. Infect Immun. 1982 Jul;37(1):301–306. doi: 10.1128/iai.37.1.301-306.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Walker D. H., Mattern W. D. Rickettsial vasculitis. Am Heart J. 1980 Dec;100(6 Pt 1):896–906. doi: 10.1016/0002-8703(80)90072-1. [DOI] [PubMed] [Google Scholar]
  21. Walker D. H. Rocky Mountain spotted fever: a disease in need of microbiological concern. Clin Microbiol Rev. 1989 Jul;2(3):227–240. doi: 10.1128/cmr.2.3.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wike D. A., Tallent G., Peacock M. G., Ormsbee R. A. Studies of the rickettsial plaque assay technique. Infect Immun. 1972 May;5(5):715–722. doi: 10.1128/iai.5.5.715-722.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES